CAO Group Recalls SHEER DesenZ Desensitizing Treatment Due to cGMP Violations
CAO Group, Inc. is recalling SHEER DesenZ Desensitizing Treatment because cGMP violations were noted during the firm's most recent inspection.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. The source text cites cGMP violations without reporting specific injuries or illnesses, aligning with a Moderate severity rating.
Plain-English summary
CAO Group, Inc. is recalling SHEER DesenZ Desensitizing Treatment, a prescription-only product containing Potassium Nitrate 12mg per film. The recall involves 71 cartons of the product, which were distributed nationwide in the US.
The recall was initiated because current Good Manufacturing Practice (cGMP) violations were noted during the firm's most recent inspection. The affected lots are # 170626 (expiration date 6/26/2019) and # 180131 (expiration date 01/31/2020).
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- SHEER DesenZ Desensitizing Treatment, Rx Only, Potassium Nitrate 12mg per film. CAO GROUP, INC, 4628 West Skyhawk Drive West Jordan, UT 84084. UPC: 8 72320 00072 1 NDC 1406000304
- Manufacturer
- CAO Group, Inc.
- Category
- Drug — Dental / Oral Care
- Hazard
- Affected units
- 71
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot # 170626
- EXP 6/26/2019
- and 180131
- EXP 01/31/2020
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by CAO Group, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · CAO Group, Inc.
See all →- ModerateCAO Group Recalls fas.TRACT Hemostatic Gel Due to cGMP Violations
FDA (Drugs) · 2018-12-19
- ModerateCAO Group Recalls FastStat Topical Hemostat Kits Due to cGMP Violations
FDA (Drugs) · 2018-12-19
- ModerateCAO Group Recalls BeeGentle Topical Anesthetic Due to cGMP Violations
FDA (Drugs) · 2018-12-19
Same hazard · cGMP violation
See all →- HighHand Sanitizer Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-02-08
- ModeratePyrogenium Homeopathic Remedy Recalled for Manufacturing Process Violations
FDA (Drugs) · 2022-06-22
- ModerateDrug Recall: PAINAID Tablets for Manufacturing Deviations
FDA (Drugs) · 2022-02-09
- ModerateDrug Recall: PEPTIME Energy Caffeine Tablets cGMP Violations
FDA (Drugs) · 2022-02-09
- ModerateCalvin Scott Recalls Diethylpropion Tablets Due to Stability Deviations
FDA (Drugs) · 2020-10-14
Similar recalls
- ModerateWalgreens Nasal Decongestant Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2018-10-24
- ModerateTG United Recalls CPM PSE Drops Due to CGMP Deviations
FDA (Drugs) · 2013-06-12
- ModerateDesonide Ointment Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateMasterPharm Recalls Calcium Citrate Powder Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05
- HighMENOW Sunscreen Powder Recalled for cGMP Deviations in California
FDA (Drugs) · 2026-09-30
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19